Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma

Ticker(s): TGTX, BMY, BAYRY

Who's the expert?

A hematologist or oncologist with knowledge about TG Therapeutics’ pipeline in Lymphoma.

Interview Questions
Q1.

Please tell us about your clinical experience. How many patients with leukemia (MZL/ FL) do you currently treat? What treatments do you use?

Added By: slingshot_insights
Q2.

Please tell us about Umbralisib’s PI3Kδ/CK1ε pathway mechanism. In what patient circumstances would you recommend umbralisib? When would you choose it over Revlimid?

Added By: slingshot_insights
Q3.

Umbralisib has previously been granted BTD & ODD in MZL but not in FL. How important is this aspect? And what can you tell us about Bayer’s Aliqopa (copanlisib- also BTD ) in comparison to that?

Added By: slingshot_insights
Q4.

TG Therapeutics cites an improved tolerability profile over 1st generation compounds and a once daily dosing schedule vs twice daily for 1st generation compounds. Are those meaningful advances that you’d consider when prescribing a treatment? Have there been issues regarding tolerability/dosing in your other treatment plans before?

Added By: slingshot_insights
Q5.

Celgene’s lenalidomide (REVLIMID) has been approved in FL and MZL half year ago based on AUGMENT and MAGNIFY trial. Have you been using it? What’s your impression so far?

Added By: slingshot_insights
Q6.

In TGTX’s MZL trial, 86% of patients (36/42) had a reduction in tumor burden; median time to initial response was 2.7 months, and maximum percentage change from baseline SPD was on average 52% ORR/ 19% CR. What are your thoughts on this data?

Added By: slingshot_insights
Q7.

.In the same trial, there were 3 grade 3 infections reported (bronchitis, pneumonia, and influenza). How much of a concern is it to you?

Added By: slingshot_insights
Q8.

According to the company, R2 : recently approved Revlimid plus Rituxan– can cause severe neutropenia and rash and secondary malignancy risks • less than half of patients respond to Ibrutinib + tolerability issues • PI3K Delta inhibitors: 3 approved for FL but with tolerability issues. How true are those statements, judging from your experience?

Added By: slingshot_insights
Q9.

 What percent of your patients fail first-line therapies? What is your usual follow-up treatment plan?

Added By: slingshot_insights
Q10.

 How likely would you be to put refractory FL or MZL patients on Umbralisib?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.